185 related articles for article (PubMed ID: 33836800)
1. A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma.
Lin C; Ballah T; Nottage M; Hay K; Chua B; Kenny L; Thomas P; Teng M; Keller J; Le T; Edmunds J; Hughes B
Radiat Oncol; 2021 Apr; 16(1):69. PubMed ID: 33836800
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin.
Nottage MK; Lin C; Hughes BG; Kenny L; Smith DD; Houston K; Francesconi A
Head Neck; 2017 Apr; 39(4):679-683. PubMed ID: 28032670
[TBL] [Abstract][Full Text] [Related]
3. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.
Stratigos AJ; Garbe C; Dessinioti C; Lebbe C; Bataille V; Bastholt L; Dreno B; Concetta Fargnoli M; Forsea AM; Frenard C; Harwood CA; Hauschild A; Hoeller C; Kandolf-Sekulovic L; Kaufmann R; Kelleners-Smeets NWJ; Malvehy J; Del Marmol V; Middleton MR; Moreno-Ramirez D; Pellecani G; Peris K; Saiag P; van den Beuken-van Everdingen MHJ; Vieira R; Zalaudek I; Eggermont AMM; Grob JJ;
Eur J Cancer; 2020 Mar; 128():83-102. PubMed ID: 32113942
[TBL] [Abstract][Full Text] [Related]
4. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
Taugner J; Käsmann L; Eze C; Rühle A; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2021 Aug; 39(4):1189-1196. PubMed ID: 33704621
[TBL] [Abstract][Full Text] [Related]
5. Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma-randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol.
Modesto A; Tougeron D; Tremolières P; Ronchin P; Jouve AD; Leignel DA; Vendrely V; Riou O; Martin-Babau J; Le Sourd S; Mirabel X; Leroy T; Huguet F; Montaigne L; Baumgaertner I; Deslandres M; Moyal E; Seva C; Selves J; Otal P; Pezzella V; Guimbaud R; Filleron T; Quéro L
BMC Cancer; 2023 Oct; 23(1):966. PubMed ID: 37828434
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
7. Locally Advanced, Unresectable Non-Small Cell Lung Cancer.
Puri S; Saltos A; Perez B; Le X; Gray JE
Curr Oncol Rep; 2020 Mar; 22(4):31. PubMed ID: 32140986
[TBL] [Abstract][Full Text] [Related]
8. Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma.
Ogata D; Tsuchida T
Curr Treat Options Oncol; 2019 Mar; 20(4):30. PubMed ID: 30874952
[TBL] [Abstract][Full Text] [Related]
9. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
10. PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California.
In GK; Vaidya P; Filkins A; Hermel DJ; King KG; Ragab O; Tseng WW; Swanson M; Kokot N; Lang JE; Menendez L; DeClerck B; Kim G; Hu JC; Terando A; Jadvar H; Ricker C; Miller KA; Peng DH; Wysong A
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1803-1811. PubMed ID: 33210210
[TBL] [Abstract][Full Text] [Related]
11. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
Rajappa S; Sharma S; Prasad K
Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
[TBL] [Abstract][Full Text] [Related]
12. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
Bozorgmehr F; Chung I; Christopoulos P; Krisam J; Schneider MA; Brückner L; Mueller DW; Thomas M; Rieken S
BMC Cancer; 2020 Aug; 20(1):806. PubMed ID: 32842974
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial.
Kuon J; Hommertgen A; Krisam J; Lasitschka F; Stenzinger A; Blasi M; Bozorgmehr F; Maenz M; Kieser M; Schneider M; Thomas M
Trials; 2020 Apr; 21(1):352. PubMed ID: 32321565
[TBL] [Abstract][Full Text] [Related]
14. Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited).
Patel P; Alrifai D; McDonald F; Forster M;
Br J Cancer; 2020 Dec; 123(Suppl 1):18-27. PubMed ID: 33293672
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
[TBL] [Abstract][Full Text] [Related]
16. ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with
Hegi-Johnson F; Rudd SE; Wichmann C; Akhurst T; Roselt P; Trinh J; John T; Devereux L; Donnelly PS; Hicks R; Scott AM; Steinfort D; Fox S; Blyth B; Parakh S; Hanna GG; Callahan J; Burbury K; MacManus M
BMJ Open; 2022 Nov; 12(11):e056708. PubMed ID: 36400733
[TBL] [Abstract][Full Text] [Related]
17. Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group).
Day F; Sridharan S; Lynam J; Gedye C; Johnson C; Fraser A; Thompson SR; Michael M; Leong T; Roy A; Kumar M; van der Westhuizen A; Quah GT; Mandaliya H; Mallesara G; Sappiatzer J; Oldmeadow C; Martin J
BMC Cancer; 2022 Dec; 22(1):1324. PubMed ID: 36528772
[TBL] [Abstract][Full Text] [Related]
18. High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial.
Lertbutsayanukul C; Kitpanit S; Kannarunimit D; Chakkabat C; Oonsiri S; Thephamongkhol K; Puataweepong P; Katanyoo K; Sukhaboon J; Tovanabut C; Chongsathientham S; Treeratsapanich P; Soonthornrak J; Prayongrat A
Trials; 2022 Oct; 23(1):897. PubMed ID: 36273186
[TBL] [Abstract][Full Text] [Related]
19. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus.
Hurt CN; Nixon LS; Griffiths GO; Al-Mokhtar R; Gollins S; Staffurth JN; Phillips CJ; Blazeby JM; Crosby TD
BMC Cancer; 2011 Oct; 11():466. PubMed ID: 22035459
[TBL] [Abstract][Full Text] [Related]
20. Stage IV cutaneous squamous cell carcinoma: treatment outcomes in a series of 42 patients.
Chapalain M; Baroudjian B; Dupont A; Lhote R; Lambert J; Bagot M; Lebbe C; Basset-Seguin N
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1202-1209. PubMed ID: 31587382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]